Abstract
Sphingosine kinase (SK) 1 and 2 are lipid kinases that phosphorylate sphingosine to form sphingosine-1 phosphate, a potent signalling molecule with pleiotrophic effects. SK1 is commonly up-regulated in tumours and its inhibition or genetic ablation has been shown to slow tumour growth as well as sensitise cancer cells to other chemotherapeutics. Therefore, SK1 is of particular interest as a target therapeutic intervention in cancer. Initial SK inhibitors were sphingosine derivatives and displayed efficacy in a number of disease models, establishing a premise for SK inhibition for anti-proliferative and anti-inflammatory therapies, even though these compounds had questionable specificity. More recently, a number of new SK inhibitors have been developed that display higher affinities and greater specificity for the SKs. Here we summarise the current small molecule inhibitors and related approaches for targeting the SKs, and their in vitro and in vivo efficacy. Furthermore, we highlight findings demonstrating the success of SK inhibition in cancer and a range of other disease models that promotes the continued interest in targeting the SKs for therapeutic benefit.
Keywords: Sphingosine kinase, sphingosine 1-phosphate, inhibitor, sphingosine, lipid kinase, cancer therapy
Current Cancer Drug Targets
Title: Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Volume: 10 Issue: 4
Author(s): M.R. Pitman and S.M. Pitson
Affiliation:
Keywords: Sphingosine kinase, sphingosine 1-phosphate, inhibitor, sphingosine, lipid kinase, cancer therapy
Abstract: Sphingosine kinase (SK) 1 and 2 are lipid kinases that phosphorylate sphingosine to form sphingosine-1 phosphate, a potent signalling molecule with pleiotrophic effects. SK1 is commonly up-regulated in tumours and its inhibition or genetic ablation has been shown to slow tumour growth as well as sensitise cancer cells to other chemotherapeutics. Therefore, SK1 is of particular interest as a target therapeutic intervention in cancer. Initial SK inhibitors were sphingosine derivatives and displayed efficacy in a number of disease models, establishing a premise for SK inhibition for anti-proliferative and anti-inflammatory therapies, even though these compounds had questionable specificity. More recently, a number of new SK inhibitors have been developed that display higher affinities and greater specificity for the SKs. Here we summarise the current small molecule inhibitors and related approaches for targeting the SKs, and their in vitro and in vivo efficacy. Furthermore, we highlight findings demonstrating the success of SK inhibition in cancer and a range of other disease models that promotes the continued interest in targeting the SKs for therapeutic benefit.
Export Options
About this article
Cite this article as:
Pitman M.R. and Pitson S.M., Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics, Current Cancer Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/156800910791208599
DOI https://dx.doi.org/10.2174/156800910791208599 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
- Sinus Node If Channel Inhibition – A New Therapeutic Approach to Heart Rate Lowering
Current Drug Therapy Nicotinamide Phosphoribosyltransferase as a Target in Inflammation- Related Disorders
Current Topics in Medicinal Chemistry The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery An Approach to Whole-Genome Identification of IRES Elements
Current Genomics Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology The GLUTs Family - Lessons from Transgenic Mice
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design An Arylidene-Thiazolidinedione Derivative, GPU-4, without PPARγ Activation, Reduces Retinal Neovascularization
Current Neurovascular Research Sex-Genetic Interaction in the Risk for Cerebrovascular Disease
Current Medicinal Chemistry Determinants of Human Coronary Collaterals
Current Cardiology Reviews Natural AMPK Activators: An Alternative Approach for the Treatment and Management of Metabolic Syndrome
Current Medicinal Chemistry Cell Sheet-Based Myocardial Tissue Engineering: New Hope for Damaged Heart Rescue
Current Pharmaceutical Design Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry Mechanisms of Cardioprotection of Halogenated Agents During Extracorporeal Circulation in Cardiac Surgery
Current Vascular Pharmacology Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Anti-Inflammatory Agents in Ageing and Age-Associated Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Peroxynitrite-Driven Mechanisms in Diabetes and Insulin Resistance – the Latest Advances
Current Medicinal Chemistry Stem Cells Derived from Human Exfoliated Deciduous Teeth (SHED) in Neuronal Disorders: A Review
Current Stem Cell Research & Therapy